3710 – 33rd Street NW
Alberta Beach, AB T2L 2M1
Canada
(403) 455-7727
https://www.xortx.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 2
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Allen Warren Davidoff Ph.D. | Founder, CEO, President & Director | 337,79k | S.O. | 1960 |
Mr. James Neville Fairbairn C.A., C.P.A., ICD.D | Chief Financial Officer | 76,2k | S.O. | 1963 |
Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer | 200,23k | S.O. | 1950 |
Dr. Stacy Evans M.B.A., M.D. | Chief Business Officer | 280k | S.O. | 1974 |
Nick Rigopoulos | Director of Communications | S.O. | S.O. | S.O. |
Dr. David Sans M.B.A., Ph.D. | Director of Corporate Development | S.O. | S.O. | 1970 |
Dr. David MacDonald Ph.D. | Consultant of Clinical Operations | S.O. | S.O. | 1964 |
Ms. Charlotte May | Corporate Secretary | S.O. | S.O. | S.O. |
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
L’ISS Governance QualityScore de XORTX Therapeutics Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..